ClinicalTrials.gg
Not yet recruitingNCT07459543Updated Aug 12, 2026

A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India

A Phase 4 interventional study of Nivolumab + Relatlimab in Unresectable Melanoma and Metastatic Melanoma, sponsored by Bristol-Myers Squibb. Not yet recruiting at 11 sites in India. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 142 studies testing nivolumab in Melanoma — 32 open to participants now, 63 under way, 9 of them phase 3. Nivolumab · Melanoma.

Planned enrollment
77th of 142
40 · median 50
Started
2026
with 10 others
Phase 4
4 of 142
2 open now
Primary completion
2029-05
later than 52 of 62 live
Registered
137th of 142
by date
Lead sponsor
23 of 142
Bristol-Myers Squibb

Among the 142 studies testing nivolumab in Melanoma, this one is the 77th largest by planned enrollment, is one of 11 that started in 2026, is one of 4 in phase 4, reaches primary completion later than 52 of the 62 other live ones, and was the 137th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

32 of the 142 studies testing nivolumab in Melanoma are open now, in 12 countries. Recruiting first, the newest first:

27 more — sign in →

By country, each count listing its studies:

All 32 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing nivolumab in Melanoma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in unresectable or metastatic melanoma participants in India.

03

Conditions studied

  • Unresectable Melanoma
  • Metastatic Melanoma

Keywords

  • Skin Cancer
  • Malignant Melanoma
  • Immunotherapy
  • India
  • Nivolumab
  • Relatlimab
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Participants must have an (ECOG) performance status of ≤ 1/Lansky Performance Score ≥ 80% for minors (ages 12-17) ONLY.

Note: Participants with ECOG PS 2 are allowed if the performance status of 2 is attributable to disease burden (and not to significant comorbidity), and if the investigator and Medical Monitor agree the patient may benefit from treatment.

  • Participants must have confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) staging system (8th edition).
  • Participants must have by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per (RECIST) v1.1 criteria.
  • Participants must have completed prior radiotherapy at least 2 weeks prior to study treatment administration.
  • Individuals of (IOCBP) must not be pregnant or breastfeeding.

Exclusion criteria

Exclusion Criteria

  • Participants must not have active or .
  • Participants must not have uveal melanoma.
  • Participants must not have an active, known, or suspected disease.

Note: Participants may enroll with the following conditions:

i) type 1 diabetes mellitus; ii) hypothyroidism only requiring hormone replacement; iii) skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment; iv) conditions not expected to recur in the absence of an external trigger are permitted to enroll.

- Participants must not have a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalent) or other medications within 14 days of start of study treatment.

Note: Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

  • Participants must not have a history of myocarditis.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Administration of Nivolumab + Relatlimab Fixed-Dose Combination (FDC)

    Drug: Nivolumab + Relatlimab

Interventions

  • DrugNivolumab + Relatlimab

    Drug pages: Nivolumab · Relatlimab

    Specified dose on specified days

    Also known as: Relopduo, BMS-986213

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to 30 weeks

  2. Incidence of drug-related AEs

    Time frame: Up to 30 weeks

  3. Incidence of serious adverse events (SAEs)

    Time frame: Up to 30 weeks

  4. Incidence of drug-related SAEs

    Time frame: Up to 30 weeks

  5. Incidence of immune-mediated adverse events (IMAEs)

    Time frame: Up to 30 weeks

  6. AEs leading to discontinuation of treatment

    Time frame: Up to 30 weeks

  7. Number of deaths

    Time frame: Up to 30 weeks

  8. Number of participants with laboratory abnormalities

    Time frame: Up to 30 weeks

Secondary outcomes

  1. Objective response rate (ORR) as assessed by investigator, using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to 30 weeks

07

Study locations

11 sites
  • Local Institution - 0012
    Nashik, Dādra and Nagar Haveli and Damān and Diu 422001, India
    • Site 0012 · Contact
  • Local Institution - 0010
    Mumbai, Maharashtra 400052, India
    • Site 0010 · Contact
  • Local Institution - 0009
    Navi Mumbai, Maharashtra 400614, India
    • Site 0009 · Contact
  • Local Institution - 0008
    Pune, Maharashtra 411017, India
    • Site 0008 · Contact
  • Local Institution - 0003
    Bhubaneswar, Odisha 751007, India
    • Site 0003 · Contact
  • Local Institution - 0011
    Bhubaneswar, 751019, India
    • Site 0011 · Contact
  • Local Institution - 0002
    Chennai, 600006, India
    • Site 0002 · Contact
  • Local Institution - 0006
    Mumbai, 400 012, India
    • Site 0006 · Contact
  • Local Institution - 0005
    Nagpur, 440001, India
    • Site 0005 · Contact
  • Local Institution - 0004
    New Delhi, 110029, India
    • Site 0004 · Contact
  • Local Institution - 0001
    New Delhi, 110085, India
    • Site 0001 · Contact
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for May 2029, 30 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 9, 2026
StartEst.
Nov 15, 2026
Primary completionEst.
May 26, 2029
CompletionEst.
May 28, 2029
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07459543
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Nov 15, 2026 (estimated)
Primary completion
May 26, 2029 (estimated)
Completion
May 28, 2029 (estimated)
Last update
Aug 12, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Relatlimab

Start the discussion